or aryl; and R^2=Cl or CF_3.

10. The composition of claim **9**, wherein R^1 is selected from the group consisting of H, CH_3, $CH(CH_3)_2$ and $C(CH_3)_3$.

11. The composition of claim **9**, wherein R^1 is selected from the group consisting of Na^+ and $CH_3N^+(CH_2OH)_3$.

12. The composition of claim **9**, wherein R^2 is Cl.

13. The composition of claim **9**, wherein R^2 is CF_3.

14. The composition of claim **9**, wherein between about 0.001 and about 100 μg/eye of a compound of formula (I) is administered.

15. The composition of claim **14**, wherein between about 0.01 and about 100 μg/eye of a compound of formula (I) is administered.

16. The composition of claim **15**, wherein between about 0.05 and about 10 μg/eye of a compound of formula (I) is administered.

17. A method of treating glaucoma and ocular hypertension, which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:



(I)

wherein: R^1=a pharmaceutically acceptable ester moiety; and R^2=Cl or CF_3.

18. The method of claim **17**, wherein R^2 is Cl.

19. The method of claim **17**, wherein R^2 is CF_3.

20. The method of claim **17**, wherein between about 0.001 and about 1000 μg\eye of a compound of formula (I) is administered.

* * * * *